Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced recently that its oral psoriasis treatment ICOTYDE (icotrokinra) achieved sustained skin clearance rates through 52 weeks in Phase 3 clinical …
Johnson & Johnson Reports Psoriasis Drug Results From Phase 3 Studies Read More
HORSHAM, PA — STRATA Skin Sciences Inc. (NASDAQ: SSKN) said a February 2026 systematic review and meta-analysis published in the Journal of Drugs in Dermatology found that 308 nm excimer …
STRATA Cites Study on Excimer Laser for Psoriasis Read More HORSHAM, PA — STRATA Skin Sciences Inc. (Nasdaq: SSKN) highlighted a February 2026 systematic review and meta-analysis that found the 308 nm excimer laser to be clinically effective in treating …
STRATA Cites Study Supporting 308 Nm Laser for Psoriasis Read More SPRING HOUSE, PA — A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective …
New Study Finds Psoriasis Patients Favor Oral Treatments Over Injections Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 …
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis Read More HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the publication of new peer-reviewed research in Lasers in Medical Science demonstrating that its XTRAC 308nm Excimer Laser, when combined …
STRATA Study Shows Excimer Laser Plus Tacrolimus Boosts Psoriasis Outcomes Read More SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra, a once-daily oral peptide therapy targeting the …
Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis Read More SPRING HOUSE, PA — Johnson & Johnson has unveiled new data from Phase 3 trials for icotrokinra (JNJ-2113), an investigational oral peptide targeting the IL-23 receptor, showing significant promise for treating …
Johnson & Johnson Advances Psoriasis Treatment with Promising Icotrokinra Results Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra (JNJ-2113), a groundbreaking oral peptide designed to selectively block …
Johnson & Johnson Reports Promising Results for Psoriasis Treatment Study Read More
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through its subsidiary, Paladin Pharma Inc. This strategic move …
Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market Read More